Poor outcome of HIV-infected patients with plasmablastic lymphoma: results from the German AIDS-related lymphoma cohort study
Schommers, Philippa,*; Wyen, Christopha,*; Hentrich, Marcusb; Gillor, Daniela; Zoufaly, Alexanderc; Jensen, Bjoernd; Bogner, Johannes R.e; Thoden, Janf; Wasmuth, Jan C.g; Fätkenheuer, Gerda; Hoffmann, Christianh
aFirst Department of Internal Medicine, University of Cologne, Cologne
bDepartment of Hematology and Oncology, Hospital Harlaching, Munich
cDepartment of Medicine I, University Medical Center Hamburg-Eppendorf, Hamburg
dDepartment of Gastroenterology, Hepatology and Infectiology, Düsseldorf University Hospital, Düsseldorf
eDepartment of Internal Medicine IV, Department of Infectious Diseases, University of Munich, Munich
fDepartment of Internal Medicine, University Hospital of Freiburg, Freiburg
gDepartment of Internal Medicine I, University of Bonn, Bonn
hICH Study Center, Hamburg/University of Schleswig Holstein, Campus Kiel, Kiel, Germany.
*Philipp Schommers and Christoph Wyen contributed equally to the writing of the article.
Correspondence to Dr Christoph Wyen, First Department of Internal Medicine, University Hospital of Cologne, Joseph Stelzmann Str. 9, 50924 Cologne, Germany. Tel: +49 221 478 3324; fax: +49 221 478 5915; e-mail: firstname.lastname@example.org
Received 23 May, 2012
Revised 9 December, 2012
Accepted 17 December, 2012
Out of 302 AIDS-related lymphoma (ARL) patients enrolled in the German ARL cohort study, 18 patients had plasmablastic lymphoma (PBL). Twelve out of 18 patients (67%) have died with a median survival of 4 months (range 0–11 months). In univariate analysis, an intermediate or high international prognostic index score was associated with a significantly lower overall survival and progression-free survival. The predominant cause of death was progressive lymphoma (67%). Our data indicate that the outcome of AIDS-related PBL is still very poor.
Since the introduction of combination antiretroviral therapy (cART), the incidence of AIDS-related lymphomas (ARLs) has remarkably declined while the prognosis has considerably improved [1,2]. However, ARLs still remain a serious cause of mortality and morbidity in HIV-infected patients . Plasmablastic lymphomas (PBLs), which are characterized by the absence of B-cell markers (CD20) and the presence of plasma cell markers, comprise a rare entity within ARL [4–8]. The aim of the present study was to describe the clinical characteristics and to analyze the outcome of HIV-infected patients with PBL enrolled in the prospective German ARL-cohort study.
The German ARL-cohort study is a prospective observational multicenter evaluation. HIV-1-infected patients with ARL diagnosed in 30 participating German centers after 1 January 2005, were included in the study. The present analysis consists of 18 patients with the histopathological diagnosis of PBL out of 302 ARL patients enrolled until June 2011. Fifteen out of 18 cases with diagnosis of PBL were confirmed by a review pathologist of one of the German lymphoma reference centers. Overall survival (OS) and progression-free survival (PFS) were calculated from the date of ARL diagnosis until death or until the last follow-up and until lymphoma progression or death as a result of any cause. Kaplan–Meier survivor function was used to evaluate OS and PFS. Prior AIDS-defining illness, CD4 T-cell count at ARL diagnosis, cART before ARL diagnosis, suppressed HIV-RNA, age more than 60, enhanced lactate dehydrogenase (LDH), Eastern Cooperative Oncology Group (ECOG)  score >2, stage III/IV disease, extranodal involvement, and the International Prognostic Index (IPI)  were considered as potential predictors (definitions of ECOG, IPI, and Ann Arbor score  are listed in Table 1). Approval was granted by the ethic committee of the University of Cologne, Germany and of each participating site. Written informed consent was obtained.
All patients were men with a median age of 44 years. Median CD4 T-cell count at ARL diagnosis was 85/μl (range 0–1100/μl). Only five patients had an undetectable HIV-RNA at the time of PBL diagnosis. The baseline characteristics are depicted in Table 1.
With regard to histopathological findings, all PBLs were CD20-negative and at least one plasma cell marker (VS38c, CD38, MUM1, CD138) has been expressed in 82% of cases. Data on KI-67 and Epstein–Barr virus (EBV) are available for 94 and 78% of cases, respectively. A very high proliferation index (KI-67 ≥80%) was found in 13 out of 17 patients (76%) and EBV positivity was observed in 12 out of 14 cases (86%).
Protocols based on CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) were the initial regimen (CHOP-21: n = 6, CHOP-14: n = 3, CHOEP: n = 1) in 10 patients, whereas seven patients were treated according to the high-dose methotrexate-based B-ALL protocol adapted from B-ALL/NHL2002 (ClinicalTrials.gov identifiers NCT00199082/NCT00388193) of the German Multicenter Study Group for the Treatment of Adult Acute Lymphoblastic Leukemia (GMALL). Twelve patients (67%) received at least four cycles of chemotherapy according to the CHOP protocol or B-ALL protocol.
By 30 June, 2011, 12 out of 18 patients (67%) have died after a median survival time of 4 months (range 0–11 months; Table 1). None of these patients achieved a complete remission. Six patients were still alive in their first complete remission with a median follow-up of 32 months (range 21–76 months). The median survival of the entire cohort of patients was 5 months (range 0–76 months). By univariate analysis, an increased LDH, an ECOG performance >2, an age >60 years at lymphoma diagnosis, and an intermediate or high IPI score (score 2–5) were associated with a significantly lower OS and PFS (OS: P = 0.003, P = 0.006, P < 0.001 and P = 0.023, respectively; PFS: P = 0.015, P < 0.001, P < 0.001 and P = 0.011, respectively). A CD4 T-cell count less than 200/μl was associated with a lower PFS (P = 0.036). No other clinical or histopathological characteristics were found to be predictive for outcome and we did not observe any difference concerning proliferation index (KI-67 <80 vs. ≥80%) and histopathological EBV detection (EBV positivity yes or no) in patients who died or survived. The predominant cause of death was lymphoma progression (n = 8, 67%). Other reasons for death were liver failure, infection, and gastrointestinal bleeding.
PBLs predominately occur in patients with advanced HIV infection and account for approximately 3% of all ARLs [12,13]. Data from the pre-cART era showed that PBL carried a poor prognosis with a median survival of about 6 months .
The data of this cohort indicate that HIV-infected patients with PBL still have a very poor outcome and OS similar to that reported in the pre-cART era [12,13]. These findings are in contrast to the improvement in survival among patients with other HIV-associated lymphoproliferative disorders [15,16] and to the findings of a recently published large retrospective analysis of 50 HIV-infected patients with PBL. The complete response in this analysis rate was 66% and the median OS was 11 months . A possible explanation for the shorter OS of our patients could be the more profound immune deficiency (median CD4 cell count 85 vs. 206/μl). As in other studies , we observed a significantly reduced survival in patients with intermediate or high IPI score.
Most of our patients received protocols based on the CHOP regimen. Of note, there were at least three patients achieving long-term complete remissions with this approach. We were unable to identify individual factors of these patients accounting for the favorable outcome. We did not observe an improved outcome in patients treated with the more intensive B-ALL protocol (P = 0.60).
ARL patients with a good performance status may also benefit from high-dose chemotherapy followed by stem cell transplantation [19,20]. Unfortunately, this approach may apply only to a subgroup of patients. Moreover, our experiences and other observations [17,21] do not suggest that intensive chemotherapies increase prognosis in patients with HIV-associated PBL.
Thus, new strategies are needed. New options may be the use of drugs such as lenalidomide or bortezomib, which has been approved for the treatment of multiple myeloma . There are several case reports of patients with PBL in which encouraging responses were achieved with these new approaches [23–25].
In conclusion, AIDS-related PBL still has a very poor prognosis. Innovative studies focusing on more specific treatment approaches are warranted.
Conflicts of interest
This work was funded by the Federal Ministry of Education and Research (BMBF), Germany; Grant: 01 KI 0771. C.W. has received consulting fees from Boehringer Ingelheim, fees for speaking engagements from Bristol-Myers Squibb, Gilead Sciences, ViiV Healthcare, MSD, Janssen-Cilag, Essex, Pfizer, and Abbott. J.R.B. has received consulting fees from Abbott, Boehringer Ingelheim, MSD, Janssen-Cilag and fees for speaking engagements from Abbott, Astellas, AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Gilead Sciences, Janssen-Cilag, ViiV Healthcare, MSD, Pfizer, Roche, and Novartis. B.J. has received consulting fees from Boehringer Ingelheim, fees for speaking engagements from Janssen-Cilag. M.H. has received support for travel to meetings from Harlachinger Krebshilfe, Celgene, Janssen-Cilag, Novartis, Pfizer, Roche Pharma, consulting fees from Takeda Pharma GmbH and fees for speaking engagements from Boehringer Ingelheim, Celgene, Gilead Sciences, MSD, Novartis, Pfizer, Roche Pharma. G.F. has received consulting fees from Abbott, Bristol-Myers Squibb, Boehringer Ingelheim, MSD, Janssen-Cilag, Gilead, and ViiV Healthcare and fees for speaking engagements from Abbott, Astellas, AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Gilead Sciences, Janssen-Cilag, ViiV Healthcare, MSD, Pfizer, and Roche. C.H. has received consulting fees from Abbott, Bristol-Myers Squibb, Gilead Sciences, Janssen-Cilag, MSD, Roche, ViiV Healthcare, fees for board membership from Abbott, BMS, Gilead Sciences, Janssen-Cilag, MSD, Roche, ViiV Healthcare and fees for speaking engagements from Abbott, BMS, Gilead Sciences, Janssen-Cilag, MSD, Roche, ViiV Healthcare. A.Z. received fees for speaking engagements and a research grant from MSD, and support for travel to meetings from Boehringer Ingelheim, Gilead Sciences, and MSD. J.T. received fees for speaking engagements from Gilead Sciences, Bristol-Myers Squibb, Actelion, and Pfizer. For the remaining authors, none were declared.
1. Diamond C, Taylor TH, Im T, Anton-Culver H. Presentation and outcomes of systemic non-Hodgkin's lymphoma: a comparison between patients with acquired immunodeficiency syndrome (AIDS) treated with highly active antiretroviral therapy and patients without AIDS. Leuk Lymphoma 2006; 47:1822–1829.
2. Spina M, Carbone A, Vaccher E, Gloghini A, Talamini R, Cinelli R, et al. Outcome in patients with nonhodgkin lymphoma and with or without human immunodeficiency virus infection. Clin Infect Dis 2004; 38:142–144.
3. Bohlius J, Schmidlin K, Costagliola D, Fatkenheuer G, May M, Caro Murillo AM, et al. Prognosis of HIV-associated non-Hodgkin lymphoma in patients starting combination antiretroviral therapy. AIDS 2009; 23:2029–2037.
4. Teruya-Feldstein J, Chiao E, Filippa DA, Lin O, Comenzo R, Coleman M, et al. CD20-negative large-cell lymphoma with plasmablastic features: a clinically heterogenous spectrum in both HIV-positive and -negative patients. Ann Oncol 2004; 15:1673–1679.
5. Colomo L, Loong F, Rives S, Pittaluga S, Martinez A, Lopez-Guillermo A, et al. Diffuse large B-cell lymphomas with plasmablastic differentiation represent a heterogeneous group of disease entities. Am J Surg Pathol 2004; 28:736–747.
6. Hoffmann C, Tiemann M, Schrader C, Janssen D, Wolf E, Vierbuchen M, et al. AIDS-related B-cell lymphoma (ARL): correlation of prognosis with differentiation profiles assessed by immunophenotyping. Blood 2005; 106:1762–1769.
7. Castillo J, Pantanowitz L, Dezube BJ. HIV-associated plasmablastic lymphoma: lessons learned from 112 published cases. Am J Hematol 2008; 83:804–809.
8. Hsi ED, Lorsbach RB, Fend F, Dogan A. Plasmablastic lymphoma and related disorders. Am J Clin Pathol 2011; 136:183–194.
9. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5:649–655.
10. Shipp MA, Harrington DP, Anderson JR, Armitage JO, Bonadonna G, Brittinger G, et al. A predictive model for aggressive non-hodgkins-lymphoma. N Engl J Med 1993; 329:987–994.
11. Lister TA, Crowther D, Sutcliffe SB, Glatstein E, Canellos GP, Young RC, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkins-disease: Cotswolds Meeting. J Clin Oncol 1989; 7:1630–1636.
12. Castillo JJ, Reagan JL. Plasmablastic lymphoma: a systematic review. Sci World J 2011; 11:687–696.
13. Riedel DJ, Gonzalez-Cuyar LF, Zhao XF, Redfield RR, Gilliam BL. Plasmablastic lymphoma of the oral cavity: a rapidly progressive lymphoma associated with HIV infection. Lancet Infect Dis 2008; 8:261–267.
14. Delecluse HJ, Anagnostopoulos I, Dallenbach F, Hummel M, Marafioti T, Schneider U, et al. Plasmablastic lymphomas of the oral cavity: a new entity associated with the human immunodeficiency virus infection. Blood 1997; 89:1413–1420.
15. Wyen C, Jensen B, Hentrich M, Siehl J, Sabranski M, Esser S, et al. Treatment of AIDS-related lymphomas: rituximab is beneficial even in severely immunosuppressed patients. Aids 2012; 26:457–464.
16. Hoffmann C, Schmid H, Muller M, Teutsch C, van Lunzen J, Esser S, et al. Improved outcome with rituximab in patients with HIV-associated multicentric Castleman disease. Blood 2011; 118:3499–3503.
17. Castillo JJ, Furman M, Beltrán BE, Bibas M, Bower M, Chen W, et al. Human immunodeficiency virus-associated plasmablastic lymphoma: poor prognosis in the era of highly active antiretroviral therapy. Cancer 2012; 118:5270–5277.
18. Simcock M, Blasko M, Karrer U, Bertisch B, Pless M, Blumer L, et al. Treatment and prognosis of AIDS-related lymphoma in the era of highly active antiretroviral therapy: findings from the Swiss HIV Cohort Study. Antivir Ther 2007; 12:931–939.
19. Michieli M, Mazzucato M, Tirelli U, De Paoli P. Stem cell transplantation for lymphoma patients with HIV infection. Cell Transplant 2011; 20:351–370.
20. Re A, Michieli M, Casari S, Allione B, Cattaneo C, Rupolo M, et al. High-dose therapy and autologous peripheral blood stem cell transplantation as salvage treatment for AIDS-related lymphoma: long-term results of the Italian Cooperative Group on AIDS and Tumors (GICAT) study with analysis of prognostic factors. Blood 2009; 114:1306–1313.
21. Castillo JJ, Winer ES, Stachurski D, Perez K, Jabbour M, Milani C, et al. Clinical and pathological differences between human immunodeficiency virus-positive and human immunodeficiency virus-negative patients with plasmablastic lymphoma. Leuk Lymphoma 2010; 51:2047–2053.
22. Sher T, Miller KC, Lee K, Chanan-Khan A. Remission induction with lenalidomide alone in a patient with previously untreated plasmablastic myeloma: a case report. Clin Lymphoma Myeloma 2009; 9:328–330.
23. Bibas M, Grisetti S, Alba L, Picchi G, Del Nonno F, Antinori A. Patient with HIV-associated plasmablastic lymphoma responding to bortezomib alone and in combination with dexamethasone, gemcitabine, oxaliplatin, cytarabine, and pegfilgrastim chemotherapy and lenalidomide alone. J Clin Oncol 2010; 28:e704–e708.
24. Bose P, Thompson C, Gandhi D, Ghabach B, Ozer H. AIDS-related plasmablastic lymphoma with dramatic, early response to bortezomib. Eur J Haematol 2009; 82:490–492.
25. Lipstein M, O’Connor O, Montanari F, Paoluzzi L, Bongero D, Bhagat G. Bortezomib-induced tumor lysis syndrome in a patient with HIV-negative plasmablastic lymphoma. Clin Lymphoma Myeloma Leuk 2010; 10:E43–46.
© 2013 Lippincott Williams & Wilkins, Inc.